Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01352416 · ClinicalTrials.gov registry record · Phase 3
Suppression Of Atrial Fibrillation With Ranolazine After Cardiac Surgery
A Phase 3 study, sponsored by Corewell Health East.
- Terminated
- Registry status
- Phase 3
- Development phase
- 15
- Enrollment target
NCT01352416 is a Phase 3 study that was terminated before completion, run by Corewell Health East. The registered enrollment target is 15 participants.
The verdict
NCT01352416, a Phase 3 study, was terminated before completion, sponsored by Corewell Health East.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 15 participants
- Enrollment target
Study Summary
The objective of this study is to show that ranolazine is a safe, viable and potent alternative for post-operative atrial fibrillation suppression in patients undergoing cardiac surgery
Interventions
- DRUG Placebo
- DRUG Ranolazine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2010-09 |
| Est. Completion | 2012-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01352416
The ClinicalTrials.gov registry entry for NCT01352416 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Corewell Health East, which has 106 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01352416 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01352416 about?
NCT01352416 is a clinical study titled "Suppression Of Atrial Fibrillation With Ranolazine After Cardiac Surgery". The objective of this study is to show that ranolazine is a safe, viable and potent alternative for post-operative atrial fibrillation suppression in patients undergoing cardiac surgery
What is the current status of trial NCT01352416?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 15 participants. The study started on 2010-09. Estimated completion is 2012-11.
What interventions are being tested in trial NCT01352416?
The interventions under investigation include: Placebo (DRUG), Ranolazine (DRUG).
Who is sponsoring clinical trial NCT01352416?
This trial is sponsored by Corewell Health East, which has 106 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.